Advertisement
YOU ARE HERE: LAT HomeCollectionsSangstat Medical Corp
IN THE NEWS

Sangstat Medical Corp

FEATURED ARTICLES
BUSINESS
May 6, 1997 | NANCY RIVERA BROOKS
No one likes rejection, but SangStat Medical Corp. makes a business out of fighting it. SangStat develops drugs and monitoring products to improve the results of organ transplants. Among them are drugs to promote the body's acceptance of organs and to treat organ rejection.
ARTICLES BY DATE
BUSINESS
July 11, 2000 | From Bloomberg News
SangStat Medical Corp. said Monday that it pulled the liquid form of its generic version of Novartis' Neoral in the U.S. after a study showed the organ-transplant drug wasn't equivalent to Neoral. Abbott Laboratories had helped SangStat market the liquid form of the drug, called SangCya. SangStat continues to sell Gengraf, the capsule form of generic Neoral, with Abbott, a spokeswoman said.
Advertisement
BUSINESS
July 11, 2000 | From Bloomberg News
SangStat Medical Corp. said Monday that it pulled the liquid form of its generic version of Novartis' Neoral in the U.S. after a study showed the organ-transplant drug wasn't equivalent to Neoral. Abbott Laboratories had helped SangStat market the liquid form of the drug, called SangCya. SangStat continues to sell Gengraf, the capsule form of generic Neoral, with Abbott, a spokeswoman said.
BUSINESS
November 3, 1998 | Davan Maharaj
The Food and Drug Administration is expected to announce approval today of a generic version of a drug used to improve the results of organ transplants. Menlo Park-based SangStat said the FDA will give it permission to market SangCya, a generic version of cyclosporine. Company executives said they plan to sell their product 20% cheaper than Neoral, the cyclosporine formulation produced by Swiss drug maker Novartis.
BUSINESS
November 3, 1998 | Davan Maharaj
The Food and Drug Administration is expected to announce approval today of a generic version of a drug used to improve the results of organ transplants. Menlo Park-based SangStat said the FDA will give it permission to market SangCya, a generic version of cyclosporine. Company executives said they plan to sell their product 20% cheaper than Neoral, the cyclosporine formulation produced by Swiss drug maker Novartis.
BUSINESS
December 15, 2004 | From Bloomberg News
The U.S. attorney's office on Tuesday charged a former desktop publishing contractor for Merrill Lynch & Co. with insider trading for allegedly profiting from confidential merger information he learned while preparing documents there. Prosecutors accused Min T. Ma, 28, a former employee of Bowne Business Solutions, of improperly trading in shares of SangStat Medical Corp. and Applied Molecular Evolution Inc.
BUSINESS
May 6, 1997
Companies ranked by analysts' mean estimates of average annualized earnings growth over the next three to five years. *--* Projected Years of Last annualized positive quarterly earn. earn/ earn/ No. of Rank Company growth share share analysts 1 Heartport Inc. 100% 0 -$0.45 7 2 Sangstat Medical Corp 69 0 -0.27 8 3 Yahoo! Inc. 65 0 0.01 10 4 Forte Software Inc. 55 0 0.12 5 5 Arterial Vascular Engineering 50 2 0.15 5 6 Clarify Inc. 50 1 0.13 5 7 Red Brick Sys. Inc. 50 2 -0.56 7 8 Xylan Corp.
BUSINESS
August 5, 2003 | Elizabeth Douglass, Times Staff Writer
The consolidation in the biotechnology industry continued Monday as Genzyme Corp. agreed to pay $600 million in cash to acquire a Bay Area company, SangStat Medical Corp., and its lucrative drug to treat organ-transplant patients. Genzyme, based in Cambridge, Mass., offered $22.50 a share, or a 45% premium over SangStat's closing price Friday. Shares in Fremont, Calif.-based SangStat jumped $6.76, or 44%, on news of the deal, closing Monday at $22.23 on Nasdaq.
BUSINESS
May 6, 1997 | NANCY RIVERA BROOKS
No one likes rejection, but SangStat Medical Corp. makes a business out of fighting it. SangStat develops drugs and monitoring products to improve the results of organ transplants. Among them are drugs to promote the body's acceptance of organs and to treat organ rejection.
Los Angeles Times Articles
|